Ugarte SJC, Ugarte MD, González NJ

Language: Spanish
References: 17
Page: 268-280
PDF size: 388.38 Kb.

ABSTRACT

The prostate magnetic resonance imaging is the technique of choice in the management of prostate cancer, concerning its diagnosis, statification and therapeutic monitoring. Using this procedure before the prostate biopsy shows advantages and benefits for the patient's management. The use of the functional images (spectroscopy, diffusion and perfusion) allows to improve the effectiveness of the techniques; it is necessary to know their advantages and limitations for a correct interpretation. The increasing development and improvement of these techniques have led the magnetic resonance imaging to be currently included in the guidelines of clinical practice for the management of this disease.

REFERENCES

1. Ministerio de Sanidad y Consumo. La situación del cáncer en España. Centro de Publicaciones: Madrid; 2008.

2. Anuario Estadístico de Salud 2013. Dirección de registros médicos y estadísticas de salud. MINSAP; 2014. Disponible en: URL: www.sld.cu/sitios/dne/

3. Vilanova JC, Carmet J, Barceló J, Villalón M, Ruscadella N. Papel actual de la resonancia magnética en el estadiaje local del cáncer de próstata. Arch Esp Urol. 2006;59(10):1001-10.

4. Borras J, Marcos-Gragera R, Torres A, Espinas JA. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 985-2019: prostate cancer. Med Clin Barc. 2008;131(1):63-6.

5. Klotz L, Zhang L, Lam A. Clinical results of long term follow up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126-31.

6. Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized prostate cancer: current approaches and new developments. Am J Roentgenol. 2009;192:1471-80.

7. Hoeks CM, Barentsz JO, Hambrock T. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiolog. 2011;261(1):46-66.

8. Fradet V, Kurhanewicz J, Cowan JE. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiolog. 2010;256(1):176-83.

9. Tamada T, Sone T, Jo Y, Yamamoto A, Yamashita T, Egashira N, et al. Prostate cancer: relationships between post biopsy hemorrhage and tumor detectability at MR diagnosis. Radiolog. 2008;248:531-9.

10. Hegde JV, Mulkern RV, Panych LP. Multiparametric MRI of prostate cancer: an update on state of the art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging. 2013;37(5):1035-54.

11. Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, Macura KJ. Advancements in MR imaging of the prostate: from diagnostic interventions. Radiograph. 2011;31(3):677-703.

12. Nagarajan R, Margolis D, Raman S. MR spectroscopic imaging and diffusionweighted imaging of prostate cancer with gleason scores. J Magn Reson Imaging. 2012;36(3):697-703.

13. Itou Y, Nakanishi K, Narumi Y, Nishizawa Y, Tsukuma H. Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer? J Magn Reson Imaging. 2011;33(1):167-72.

14. Lee DH, Koo KC, Lee SH. Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: preliminary analysis. J Urol. 2013;190(4):1213-7.

15. Futterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiolog. 2006;241:449-58.

16. Turkbey B, Mani H, Aras O. Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiolog. 2013;268(1):144-52.

17. Vargas HA, Akin O, Afaq A. Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol. 2012;188(5):1732-8.